For patients with low-risk prostate cancer managed with active surveillance, obesity may increase risk of progression
the ONA take:
According to a new study published in the journal European Urology, researchers have found that obesity is linked with an increased risk of progression of low-risk prostate cancers in patients that are managed by active surveillance.
For the study, the researchers identified 565 men undergoing active surveillance for low-risk prostate cancer. The researchers found that during the median follow-up of 48 months, 168 men (30%) experienced pathologic progression and 172 men (30%) experienced therapeutic progression.
They did not find an association between obesity and risk of progression at the time of confirmatory biopsy, but beyond that, obesity was linked with an increased risk of pathologic progression (P = 0.007) and therapeutic progression (P = 0.007).
For every 5 unit increase in body mass index (BMI), the risk of pathologic progression increases (HR = 1.5, 95% CI: 1.1-2.1, P = 0.02). Similarly, the risk of therapeutic progression increases in the same manner (HR = 1.4, 95% CI: 1.0-1.9, P = 0.05).
Ultimately, the findings suggest that obesity is associated with a significantly elevated risk of prostate cancer progression after the confirmatory biopsy.
Obesity linked with increased risk of progression of low-risk prostate cancers in active surveillance.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
- Sexual Aids and Resources Not Readily Available at Cancer Centers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|